{
    "hands_on_practices": [
        {
            "introduction": "Before a drug can be repurposed, its basic pharmacokinetic profile must be understood. A key parameter is clearance ($CL$), which governs how quickly the drug is eliminated from the body and, consequently, the overall exposure a patient receives from a given dose. This exercise reinforces the fundamental relationship between dose ($D$), bioavailability ($F$), clearance ($CL$), and total drug exposure, as measured by the Area Under the Curve ($AUC$). By calculating clearance from clinical data and using it to predict exposure at different doses, you will practice a critical first-pass analysis to determine if a simple dose adjustment is a viable strategy for a new indication .",
            "id": "4943477",
            "problem": "A small-molecule originally approved for Indication A is being considered for drug repositioning to Indication B. In a single-dose, oral pharmacokinetics (PK) study in healthy volunteers, the measured Area Under the Concentration–Time Curve (AUC) was $20$ mg·h/L after an oral dose of $D = 100$ mg. The absolute bioavailability was independently estimated as $F = 0.5$. Assume linear, time-invariant pharmacokinetics and that the oral dose is absorbed according to the bioavailability fraction $F$.\n\nUsing only first principles for clearance and mass balance, derive the relationship between clearance $CL$ and the variables $F$, $D$, and $\\text{AUC}$, and then compute $CL$ for the data above. Express $CL$ in L/h and round your answer to three significant figures.\n\nFor the repositioned indication (Indication B), preclinical-to-clinical translational modeling suggests an efficacy target exposure of $\\text{AUC}_{\\text{target}} = 30$ mg·h/L, while the upper bound of the therapeutic window is $\\text{AUC}_{\\text{max}} = 28$ mg·h/L in the relevant patient population. Assuming the same $F$ and $CL$ as determined above, use fundamental PK scaling to assess whether simple dose escalation alone is viable for Indication B without exceeding the therapeutic window. Provide your viability assessment qualitatively; the final numerical answer to submit is the computed clearance.",
            "solution": "Begin with the definition of clearance in pharmacokinetics. Clearance $CL$ is defined as the proportionality constant that relates the rate of drug elimination to the instantaneous plasma concentration $C(t)$:\n$$\n\\text{rate of elimination}(t) = CL \\cdot C(t).\n$$\nOver the entire dosing interval for a single dose, mass balance requires that the total amount of drug entering the systemic circulation equals the total amount eliminated. For an oral dose $D$ with absolute bioavailability $F$, the systemic amount entering is $F D$. The total amount eliminated can be written as the time integral of the elimination rate:\n$$\n\\int_{0}^{\\infty} \\text{rate of elimination}(t)\\, dt = \\int_{0}^{\\infty} CL \\cdot C(t)\\, dt = CL \\int_{0}^{\\infty} C(t)\\, dt.\n$$\nBy definition, the Area Under the Concentration–Time Curve (AUC) is\n$$\n\\text{AUC} = \\int_{0}^{\\infty} C(t)\\, dt.\n$$\nEquating the total amount entering the systemic circulation to the total amount eliminated under linear, time-invariant clearance gives\n$$\nF D = CL \\cdot \\text{AUC}.\n$$\nSolving for clearance yields the fundamental relationship\n$$\nCL = \\frac{F D}{\\text{AUC}}.\n$$\n\nCompute $CL$ using the provided values $F = 0.5$, $D = 100$ mg, and $\\text{AUC} = 20$ mg·h/L:\n$$\nCL = \\frac{0.5 \\times 100\\ \\text{mg}}{20\\ \\text{mg·h/L}} = \\frac{50\\ \\text{mg}}{20\\ \\text{mg·h/L}} = 2.5\\ \\text{L/h}.\n$$\nRounded to three significant figures, the clearance is $2.50$ L/h.\n\nAssess viability of dose escalation for the repositioned indication. Under linear pharmacokinetics with unchanged $F$ and $CL$, exposure scales with dose according to\n$$\n\\text{AUC} = \\frac{F}{CL} \\, D.\n$$\nTo achieve $\\text{AUC}_{\\text{target}} = 30$ mg·h/L, solve for the required dose:\n$$\nD_{\\text{target}} = \\frac{CL}{F} \\cdot \\text{AUC}_{\\text{target}} = \\frac{2.5\\ \\text{L/h}}{0.5} \\times 30\\ \\text{mg·h/L} = 5 \\times 30\\ \\text{mg} = 150\\ \\text{mg}.\n$$\nThe resulting exposure at $D_{\\text{target}}$ is $\\text{AUC} = 30$ mg·h/L. Since the therapeutic window upper bound is $\\text{AUC}_{\\text{max}} = 28$ mg·h/L, achieving the target exposure by dose escalation alone would exceed the therapeutic window. Therefore, simple dose escalation is not viable without additional strategies (for example, formulation changes to increase $F$ without increasing $D$, altered dosing regimens, or combination therapy to modify clearance), but these are beyond the scope of the requested calculation.\n\nThe final numerical answer to submit is the computed clearance rounded as specified.",
            "answer": "$$\\boxed{2.50}$$"
        },
        {
            "introduction": "A successful drug must be both effective and safe, a balance quantified by the therapeutic index ($TI$). When repurposing a drug, this balance might be unfavorable for the new indication, requiring innovative solutions beyond simple dose adjustments. This practice explores how pharmacokinetics ($PK$) and pharmacodynamics ($PD$) can be decoupled to improve a drug's safety profile, highlighting the crucial difference between efficacy driven by total exposure ($AUC$) and toxicity driven by peak concentration ($C_{\\max}$). You will learn how advanced formulation strategies can be used to widen the therapeutic window, potentially making a drug candidate safe and effective for a new purpose .",
            "id": "5011502",
            "problem": "A small-molecule candidate is being repurposed from its original indication to treat a new fibrotic condition. From historical human data in the original indication, the median effective dose (Effective Dose 50, abbreviated as $\\mathrm{ED}_{50}$) is reported as $\\mathrm{ED}_{50} = 5\\ \\mathrm{mg}$, and the median toxic dose (Toxic Dose 50, abbreviated as $\\mathrm{TD}_{50}$) is reported as $\\mathrm{TD}_{50} = 20\\ \\mathrm{mg}$. For the new indication, early translational modeling suggests that efficacy is driven primarily by systemic exposure, and dose-ranging will begin near the historical $\\mathrm{ED}_{50}$.\n\nUsing core definitions from pharmacology, compute the therapeutic index for this drug using the provided $\\mathrm{ED}_{50}$ and $\\mathrm{TD}_{50}$. Report the therapeutic index as a unitless value. No rounding is required; report the exact value.\n\nThen, reasoning from first principles in pharmacokinetics (PK) and pharmacodynamics (PD), assess whether a modified oral formulation designed to reduce peak concentration $C_{\\max}$ while preserving total exposure (area under the concentration–time curve, $AUC$) could plausibly widen the effective therapeutic window for the new indication. Your justification must begin from foundational definitions and well-tested relationships (for example, $AUC$ scaling with dose and clearance, and the distinction between peak-driven versus exposure-driven toxicity) and proceed logically to the conclusion. Do not use any pre-derived “shortcut” formulas beyond fundamental definitions; derive any needed relationships from base PK/PD principles. The final numeric answer should only be the therapeutic index; the reasoning about formulation should be presented in your solution narrative.",
            "solution": "The problem presents two distinct tasks. First, to compute the therapeutic index from provided median effective and toxic doses. Second, to provide a reasoned assessment, based on first principles of pharmacokinetics (PK) and pharmacodynamics (PD), of how a specific modification to a drug's oral formulation could impact its therapeutic window.\n\nFirst, we address the calculation of the therapeutic index ($\\mathrm{TI}$). The therapeutic index is a quantitative measure of a drug's safety margin, representing the separation between the doses required for a therapeutic effect and the doses that produce toxicity. The standard definition for the $\\mathrm{TI}$ is the ratio of the median toxic dose ($\\mathrm{TD}_{50}$) to the median effective dose ($\\mathrm{ED}_{50}$). The $\\mathrm{TD}_{50}$ is the dose at which $50\\%$ of the population experiences a specific toxic effect, while the $\\mathrm{ED}_{50}$ is the dose at which $50\\%$ of the population experiences a desired therapeutic effect.\n\nThe formula is given by:\n$$\n\\mathrm{TI} = \\frac{\\mathrm{TD}_{50}}{\\mathrm{ED}_{50}}\n$$\nThe problem provides the following values:\n$$\n\\mathrm{ED}_{50} = 5\\ \\mathrm{mg}\n$$\n$$\n\\mathrm{TD}_{50} = 20\\ \\mathrm{mg}\n$$\nSubstituting these values into the definition:\n$$\n\\mathrm{TI} = \\frac{20\\ \\mathrm{mg}}{5\\ \\mathrm{mg}} = 4\n$$\nThe therapeutic index is a dimensionless quantity, as the units of dose in the numerator and denominator cancel. The calculated therapeutic index for this drug, based on historical data, is $4$.\n\nNext, we assess the potential impact of a modified oral formulation on the therapeutic window. The therapeutic window is the range of drug concentrations in the body that provides therapeutic efficacy with minimal toxicity. It is conceptually bounded by the Minimum Effective Concentration ($\\mathrm{MEC}$) and the Minimum Toxic Concentration ($\\mathrm{MTC}$). A wider therapeutic window is desirable as it allows for greater flexibility in dosing and a larger margin of safety.\n\nThe proposed modification involves reducing the peak plasma concentration ($C_{\\max}$) while preserving the total systemic exposure, represented by the area under the concentration-time curve ($AUC$). This profile is characteristic of an extended-release or modified-release formulation, which slows the rate of drug absorption from the gastrointestinal tract.\n\nLet us reason from first principles.\n1.  **Systemic Exposure and its Determinants:** The total systemic exposure ($AUC$) following an oral dose ($D$) is determined by the drug's bioavailability ($F$) and its systemic clearance ($CL$). The fundamental relationship is:\n    $$\n    AUC = \\frac{F \\times D}{CL}\n    $$\n    A modified formulation primarily alters the rate of absorption ($k_a$), not the extent of absorption ($F$) or the body's ability to eliminate the drug ($CL$). Therefore, for a given dose ($D$), the $AUC$ is preserved, which is consistent with the problem statement. A slower absorption rate ($k_a$) leads to a lower and later peak concentration (decreased $C_{\\max}$, increased $T_{\\max}$).\n\n2.  **Efficacy Driven by Total Exposure ($AUC$):** The problem states that for the new fibrotic indication, efficacy is primarily driven by systemic exposure ($AUC$). This implies that the therapeutic effect is a function of the cumulative or sustained presence of the drug, rather than the achievement of a high transient concentration. Since the modified formulation preserves the $AUC$ for a given dose, the total effective exposure is maintained. Consequently, the dose required to achieve a therapeutic effect should remain largely unchanged, assuming the new, lower $C_{\\max}$ still exceeds the $\\mathrm{MEC}$ for a sufficient duration.\n\n3.  **Toxicity Driven by Peak Concentration ($C_{\\max}$):** The mechanism of toxicity is not explicitly defined as peak-driven or exposure-driven. However, many dose-limiting adverse effects of small-molecule drugs are concentration-dependent and occur when plasma levels exceed a certain threshold, the $\\mathrm{MTC}$. This type of toxicity is therefore driven by the peak concentration, $C_{\\max}$. If the original formulation produced a $C_{\\max}$ that approached or exceeded the $\\mathrm{MTC}$, this would lead to dose-limiting toxicity.\n\n4.  **Synthesizing the Effect on the Therapeutic Window:** The modified formulation decouples the peak concentration from the total exposure. By specifically lowering $C_{\\max}$ while maintaining $AUC$:\n    -   **Efficacy is preserved:** Because efficacy is $AUC$-dependent, and $AUC$ is unchanged per dose.\n    -   **Toxicity is reduced:** Because toxicity is often $C_{\\max}$-dependent, and $C_{\\max}$ is lowered. The lower peak concentration is less likely to breach the $\\mathrm{MTC}$.\n\nTherefore, it is plausible that a higher dose of the modified formulation could be administered before the new, lower $C_{\\max}$ profile reaches the critical $\\mathrm{MTC}$. This effectively increases the dose required to produce toxicity. Since the dose required for efficacy (which depends on $AUC$) remains the same, the separation between the effective dose range and the toxic dose range is increased. This constitutes a widening of the therapeutic window. In summary, a modified oral formulation that reduces $C_{\\max}$ while preserving $AUC$ can plausibly improve the drug's safety profile and widen its therapeutic window, provided that efficacy is indeed $AUC$-driven and toxicity is at least partially $C_{\\max}$-driven.",
            "answer": "$$\n\\boxed{4}\n$$"
        },
        {
            "introduction": "Many drug repurposing successes stem not from the drug's intended primary effect but from its \"polypharmacology\"—its ability to bind to multiple molecular targets. The challenge lies in distinguishing inconsequential off-target interactions from those that are functionally significant at therapeutic drug concentrations. This exercise demonstrates how to use the law of mass action and the concept of fractional occupancy ($\\theta$) to quantitatively assess a drug's engagement with its various targets based on their binding affinities ($K_d$). By analyzing a drug's binding profile, you will practice identifying which off-targets are meaningfully engaged, a crucial skill for hypothesizing new mechanisms of action and discovering repositioning opportunities .",
            "id": "4943499",
            "problem": "A small-molecule ligand $X$ was discovered for a primary target $\\mathrm{P}$ but exhibits broad polypharmacology. In drug repurposing and repositioning, an evidence-based inference of a new indication can be made when off-target binding at clinically relevant exposures functionally engages a disease-relevant pathway. Consider the following scenario grounded in the law of mass action and reversible one-site binding: at equilibrium, a ligand $L$ and receptor $R$ form the complex $RL$, and the equilibrium dissociation constant $K_{d}$ quantifies binding affinity. A binding profile matrix is given by a list of $K_{d}$ values of $X$ across a set of targets, measured under standardized conditions. The free therapeutic plasma concentration of $X$ is $C_{f}=30 \\ \\mathrm{nM}$, and the following equilibrium dissociation constants are observed for $X$: for the primary target $\\mathrm{P}$, $K_{d}=10 \\ \\mathrm{nM}$; for off-targets $\\mathrm{A}$, $K_{d}=20 \\ \\mathrm{nM}$; $\\mathrm{B}$, $K_{d}=25 \\ \\mathrm{nM}$; $\\mathrm{C}$, $K_{d}=1000 \\ \\mathrm{nM}$; $\\mathrm{D}$, $K_{d}=50 \\ \\mathrm{nM}$; and $\\mathrm{E}$, $K_{d}=15 \\ \\mathrm{nM}$. Assume non-cooperative binding, identical receptor abundance across targets for interpretive purposes, and negligible active metabolites.\n\nStarting from fundamental definitions and well-tested facts in pharmacology (law of mass action; equilibrium dissociation constant; fractional occupancy; pharmacodynamic reasoning that target engagement above a threshold can be mechanistically relevant), derive how off-target binding leading to a new indication can be inferred from such a binding profile matrix. In your derivation, establish a criterion for mechanistic relevance at the exposure $C_{f}$, and use it to identify which off-targets among $\\mathrm{A}$, $\\mathrm{B}$, $\\mathrm{C}$, $\\mathrm{D}$, and $\\mathrm{E}$ plausibly contribute to pathway engagement that could motivate repositioning.\n\nTo quantify mechanistic overlap between the hypothesized repositioning mechanism and a known disease mechanism, compute the Jaccard similarity between the two target sets $A=\\{\\mathrm{A},\\mathrm{B},\\mathrm{C},\\mathrm{E}\\}$ and $B=\\{\\mathrm{B},\\mathrm{C},\\mathrm{D},\\mathrm{E}\\}$. Provide the Jaccard similarity as your final answer. Express the result as an exact fraction. No rounding is required, and the answer is unitless.",
            "solution": "The problem asks for two main tasks: first, to derive a method for inferring off-target engagement and apply it to a given dataset, and second, to compute the Jaccard similarity between two specified target sets.\n\n**Part 1: Derivation of Target Engagement Criterion**\n\nThe inference of off-target activity is based on the principle of fractional occupancy, which is derived from the law of mass action for reversible biomolecular interactions.\n\nConsider the binding of a ligand $L$ to a receptor $R$ to form a ligand-receptor complex $RL$. The interaction is described by the reversible reaction:\n$$ L + R \\rightleftharpoons RL $$\nThe rate of association is proportional to the concentrations of the free ligand and free receptor, given by $k_{on} [L] [R]$, where $k_{on}$ is the association rate constant. The rate of dissociation is proportional to the concentration of the complex, given by $k_{off} [RL]$, where $k_{off}$ is the dissociation rate constant.\n\nAt equilibrium, the rate of association equals the rate of dissociation:\n$$ k_{on} [L] [R] = k_{off} [RL] $$\nThe equilibrium dissociation constant, $K_d$, is defined as the ratio of the dissociation rate constant to the association rate constant:\n$$ K_d = \\frac{k_{off}}{k_{on}} = \\frac{[L] [R]}{[RL]} $$\n$K_d$ has units of concentration and represents the concentration of free ligand at which half of the receptors are occupied at equilibrium. A lower $K_d$ value corresponds to a higher binding affinity.\n\nThe fractional occupancy, $\\theta$, is defined as the fraction of the total receptor population, $[R]_{total}$, that is bound by the ligand:\n$$ \\theta = \\frac{[RL]}{[R]_{total}} $$\nThe total receptor concentration is the sum of the free receptor and the bound receptor concentrations:\n$$ [R]_{total} = [R] + [RL] $$\nTo express $\\theta$ in terms of $[L]$ and $K_d$, we first rearrange the definition of $K_d$ to solve for $[R]$:\n$$ [R] = \\frac{K_d [RL]}{[L]} $$\nSubstituting this into the expression for $[R]_{total}$:\n$$ [R]_{total} = \\frac{K_d [RL]}{[L]} + [RL] = [RL] \\left( \\frac{K_d}{[L]} + 1 \\right) = [RL] \\left( \\frac{K_d + [L]}{[L]} \\right) $$\nNow, we can substitute this expression for $[R]_{total}$ back into the definition of fractional occupancy:\n$$ \\theta = \\frac{[RL]}{[RL] \\left( \\frac{[L] + K_d}{[L]} \\right)} $$\nThis simplifies to the Hill-Langmuir equation for non-cooperative binding:\n$$ \\theta = \\frac{[L]}{[L] + K_d} $$\nThis equation is fundamental for pharmacodynamics. It allows us to predict the extent of target engagement ($\\theta$) for any target given its binding affinity ($K_d$) for the ligand and the free concentration of the ligand ($[L]$). In this problem, the free therapeutic plasma concentration $C_f$ corresponds to $[L]$.\n\nFor drug repurposing, we need to infer which off-targets are engaged to a degree that is mechanistically relevant at the therapeutic exposure. A widely used heuristic in pharmacology is that significant functional engagement is plausible when a target's fractional occupancy exceeds a certain threshold. A common and justifiable threshold is $50\\%$, or $\\theta \\geq 0.5$. From the Hill-Langmuir equation, this condition is met when $[L] \\geq K_d$.\n\nLet's establish this as our criterion: an off-target is considered plausibly engaged for a repositioning hypothesis if its fractional occupancy at the free therapeutic concentration $C_f$ is $50\\%$ or greater.\nGiven $C_f = 30 \\ \\mathrm{nM}$.\n\nWe now compute the fractional occupancy for each off-target:\n- **Target A:** $K_d = 20 \\ \\mathrm{nM}$. $\\theta_A = \\frac{C_f}{C_f + K_d} = \\frac{30}{30 + 20} = \\frac{30}{50} = 0.6$. Since $0.6 \\geq 0.5$, target A is plausibly engaged.\n- **Target B:** $K_d = 25 \\ \\mathrm{nM}$. $\\theta_B = \\frac{30}{30 + 25} = \\frac{30}{55} = \\frac{6}{11} \\approx 0.545$. Since $0.545 \\geq 0.5$, target B is plausibly engaged.\n- **Target C:** $K_d = 1000 \\ \\mathrm{nM}$. $\\theta_C = \\frac{30}{30 + 1000} = \\frac{30}{1030} \\approx 0.029$. Since $0.029 < 0.5$, target C is not plausibly engaged.\n- **Target D:** $K_d = 50 \\ \\mathrm{nM}$. $\\theta_D = \\frac{30}{30 + 50} = \\frac{30}{80} = \\frac{3}{8} = 0.375$. Since $0.375 < 0.5$, target D is not plausibly engaged.\n- **Target E:** $K_d = 15 \\ \\mathrm{nM}$. $\\theta_E = \\frac{30}{30 + 15} = \\frac{30}{45} = \\frac{2}{3} \\approx 0.667$. Since $0.667 \\geq 0.5$, target E is plausibly engaged.\n\nBased on this analysis, the off-targets among the given set that plausibly contribute to pathway engagement and could motivate repositioning are $\\mathrm{A}$, $\\mathrm{B}$, and $\\mathrm{E}$.\n\n**Part 2: Calculation of Jaccard Similarity**\n\nThe second part of the problem asks for the computation of the Jaccard similarity, $J(A, B)$, between two explicitly defined sets of targets. The Jaccard similarity is a measure of the similarity between two finite sets and is defined as the size of their intersection divided by the size of their union:\n$$ J(A, B) = \\frac{|A \\cap B|}{|A \\cup B|} $$\nThe given sets are:\n$$ A = \\{\\mathrm{A}, \\mathrm{B}, \\mathrm{C}, \\mathrm{E}\\} $$\n$$ B = \\{\\mathrm{B}, \\mathrm{C}, \\mathrm{D}, \\mathrm{E}\\} $$\n\nFirst, we find the intersection of the two sets, which contains all elements that are in both $A$ and $B$:\n$$ A \\cap B = \\{\\mathrm{B}, \\mathrm{C}, \\mathrm{E}\\} $$\nThe size of the intersection is the number of elements in this set:\n$$ |A \\cap B| = 3 $$\n\nNext, we find the union of the two sets, which contains all elements that are in either $A$ or $B$ or both:\n$$ A \\cup B = \\{\\mathrm{A}, \\mathrm{B}, \\mathrm{C}, \\mathrm{D}, \\mathrm{E}\\} $$\nThe size of the union is the number of elements in this set:\n$$ |A \\cup B| = 5 $$\n\nFinally, we compute the Jaccard similarity using the formula:\n$$ J(A, B) = \\frac{|A \\cap B|}{|A \\cup B|} = \\frac{3}{5} $$\nThe Jaccard similarity is an exact fraction as requested.",
            "answer": "$$\\boxed{\\frac{3}{5}}$$"
        }
    ]
}